Recurrent Squamous Cell Carcinoma of the Hypopharynx Completed Phase 2 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0029504 (Recurrent Squamous Cell Carcinoma of the Hypopharynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00103259Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckTreatment